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Abstract We describe the case of an 83-year-old man
with a family history of pulmonary hypertension (PH) who
presented with severe pulmonary arterial hypertension
(PAH) and later tested positive for a novel bone morpho-
genetic protein receptor 2 (BMPR2) gene mutation. To our
knowledge, this may be the oldest reported patient with
PAH in whom a BMPR2 mutation was initially identiﬁed.
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Abbreviations
BMPR2 Bone morphogenetic protein receptor type 2
DNA Deoxyribonucleic acid
HPAH Heritable pulmonary arterial hypertension
IPAH Idiopathic pulmonary arterial hypertension
mRNA Messenger ribonucleic acid
NMD Nonsense mediated decay
PAH Pulmonary arterial hypertension
PH Pulmonary hypertension
TGF-b Transforming growth factor-b
Introduction
Pulmonary arterial hypertension (PAH) is a rare incapaci-
tating disease with progressive functional limitation and
deterioration to right heart failure and death. In addition to
various disorders that can cause PAH, a genetic predispo-
sition to this disease was identiﬁed with the discovery of
mutations in the gene encoding the bone morphogenetic
protein receptor type 2 (BMPR2), a member of the trans-
forming growth factor-b (TGF-b) receptor, in both the
familial and the sporadic cases of PAH [1–3]. Heritable
PAH (HPAH) segregates as an autosomal-dominant dis-
order with variable age of onset, reduced penetrance,
approximately a 2:1 female:male ratio, and genetic antic-
ipation in some pedigrees [4–6]. Approximately 6% of the
individuals diagnosed with PAH have a family history of
this disorder. BMPR2 mutations are heterogeneous, with
missense, nonsense, frameshift, splice site, and both small
and large gene deletions and duplications found throughout
the gene [7, 8]. Disease-causing mutations have been
identiﬁed in approximately 70% of HPAH and 5–26% of
idiopathic PAH (IPAH) patients [8–11].
We present a novel BMPR2 mutation-associated case of
PAH ﬁrst diagnosed at 83 years of age. To the best of our
knowledge, our patient may be the oldest to be diagnosed
with BMPR2-associated PAH.
Case Report
An 83-year-old World War II veteran presented for eval-
uation of fatigue and breathlessness with exertion at New
York Heart Association III functional class with ﬁndings of
elevated right-sided pressures on echocardiogram. He gave
a history of progressive dyspnea with physical activity for
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DOI 10.1007/s00408-010-9242-74 years and pedal edema for 6 months which was sym-
metrical and worse during the evenings.
His past medical history included mild hypertension,
nocturnal hypoxemia requiring oxygen therapy, gout, and
degenerative arthritis of his right knee from shrapnel injury
during World War II. He had an episode of syncope
approximately 1 year prior to evaluation that was attributed
to dehydration and heat exhaustion. Echocardiogram done
at that time had shown preserved left ventricular ejection
fraction at 70%, enlarged right-sided chambers, and esti-
mated right ventricular systolic pressures of 80 mmHg. He
had no history of thromboembolic disease, chronic lung
disease, or prior transfusions. He was on treatment with
amlodipine for systemic hypertension, furosemide, and
oxygen.
He had been a lifelong nonsmoker with no other
dependence. He recalled his mother (nonsmoker) was
diagnosed with pulmonary hypertension (PH) and emphy-
sema and had died at age 65. His brother and a maternal
ﬁrst cousin had died with a diagnosis of PH at age 49 and
71, respectively. The patient remembered that PH was
identiﬁed on echocardiograms in his affected relatives but
did not recollect details of other diagnostic workup. One of
his brothers died of cirrhosis while his youngest brother
was alive and had a history of coronary artery disease. His
sister was alive and healthy. The patient had never married
and had no children.
On examination his blood pressure was 92/61 mmHg,
heart rate was 105/min, respiratory rate was 18–20/min,
oxygen saturation was 92% on room air, and body mass
index was 26.6 kg/m
2. Abnormal ﬁndings on examination
included accentuated pulmonic component of second heart
sound, 3/6 pansystolic murmur at the left lower sternal
border, and bilateral pitting pedal edema.
Abnormal laboratory parameters included a brain
natriuretic peptide of 335 pg/ml, serum creatinine of
1.4 mg/dl, and hemoglobin of 18 g/dl. Chest X-ray showed
cardiomegaly, prominent pulmonary vasculature, and nor-
mal lung ﬁelds. Pulmonary function tests revealed normal
spirometry, lung volumes, and diffusion capacity. Poly-
somnogram conﬁrmed sleep-disordered breathing with
obstructive, mixed, and central apneas. He was started on
nocturnal continuous positive airway pressure with oxygen
therapy. Electrocardiogram showed right axis deviation,
right ventricular hypertrophy, and inverted T waves in V1-
V4. Echocardiogram was repeated and showed marked
dilatation of right atrium and ventricle, impaired systolic
right ventricular function, moderate to severe tricuspid
regurgitation, and estimated peak pulmonary artery pres-
sures of 100 mmHg with left ventricular ejection fraction
of 55% without segmental wall motion abnormalities or
pericardial effusion. Adenosine stress test did not show
ischemia or infarction. A 6-min walk test was severely
impaired with a total distance of 67.06 m or 30.9% of the
predicted lower limit of normal calculated to be 216.8 m
for his age and body mass index using the Enright and
Sherrill formula [12]. He stopped after 3 min because of
breathlessness. Ventilation perfusion scan did not reveal
perfusion defects or ventilation perfusion mismatch. Col-
lagen vascular workup and hepatitis screen were negative,
and HIV testing was not done as he denied risk factors.
Right heart catheterization conﬁrmed pulmonary arterial
hypertension with pulmonary artery pressures of 102/
44 mmHg (mean = 63 mmHg), mean pulmonary artery
occlusive pressure of 9 mmHg, mean right atrial pressure
of 19 mmHg, mixed venous saturation of 61.5%, thermo-
dilution cardiac output of 2.72 l/min, and cardiac index and
pulmonary vascular resistance calculated at 1.48 l/min/m
2
and 1588 dyn s/cm
5, respectively. Acute vasodilator study
with inhaled nitric oxide did not show vasoreactivity.
With a family history of relatives carrying a diagnosis of
PH, genetic testing was offered to assess for the presence of
HPAH. Using previously described techniques, BMPR2
DNA and RNA mutation screening was performed upon
peripheral lymphocytes and identiﬁed mutation c.241insT
in exon 2 of the BMPR2 gene (Fig. 1)[ 8]. This disease-
causing mutation in codon 81 replaced lysine with a stop
codon.
Amlodipine was stopped and he was started on digoxin,
warfarin, and bosentan, which was titrated to a target dose
of 125 mg two times a day. At the time of his last ofﬁce
Fig. 1 Sequencing results demonstrating mutation c.241insT in DNA
and mRNA
350 Lung (2010) 188:349–352
123visit and after a year of bosentan therapy, he reported better
tolerance for physical activity with improvement in func-
tional class to NYHA II. His 6-min walk distance had
improved to 146.3 m (67.5% of predicted lower limit of
normal [12]) and was mainly limited by knee pain. Follow-
up right heart catheterization showed a right atrial mean
pressure of 3 mmHg, pulmonary artery pressure of 95/
20 mmHg (mean = 45 mmHg), pulmonary capillary
wedge pressure of 6 mmHg, cardiac output of 2.9 l/min,
and calculated cardiac index and pulmonary vascular
resistance of 1.6 l/min/m
2 and 1075 dyn s/cm
5, respec-
tively. His extended family had undergone genetic coun-
seling but declined genetic testing.
Discussion
We describe the case of an 83-year-old man presenting
with pulmonary arterial hypertension due to a previously
unreported BMPR2 mutation c.241insT. This DNA single
base insertion at codon 81 results in a frameshift with a
stop codon at this site causing premature truncation of the
BMPR2 protein. This mutation creates messenger ribonu-
cleic acid (mRNA) that would be identiﬁed and subjected
to nonsense-mediated decay (NMD) [13]. Interestingly, a
low level of aberrant mRNA was detected in the lympho-
cytes from this patient (Fig. 1).
This case is interesting in that this patient presented at the
age of 83. Recently, Sztrymf et al. [14] reported that PAH
carriers of BMPR2 mutations presented 10 years earlier
than IPAH patients (36.5 ± 14.5 vs. 46.0 ± 16.1). Carriers
of BMPR2-truncating mutations (NMD positive) have a
later age of diagnosis and death than carriers of a BMPR2
missense mutation (NMD negative) [15]. This recent study
of NMD-associated BMPR2 mutations provides additional
evidence of the protective function of NMD in heterozygote
carriers of dominant disorders [16]. Since only 10–20% of
individuals with a BMPR2 mutation develop PAH, it is
suggested that both environmental factors and modiﬁer
genes explain the reduced penetrance of HPAH [17–21].
Single nucleotide polymorphisms in the TGFb1 gene and
variations in genes associated with proliferation, GTP sig-
naling, stress response, and estrogen metabolism have been
proposed to modulate the age of diagnosis and penetrance in
these families [18, 19]. Recently, expression of wild-type
allele BMPR2 transcripts has been reported as being
important in determining penetrance of HPAH [20]. Thus,
the late age of onset in our patient can be likely explained by
a NMD-positive BMPR2 mutation and the presence of
modiﬁer genes and/or unknown environmental factors
which conveyed protection from PAH at an earlier age. It is
interesting that the mutant BMPR2 mRNA was detected at a
low level in the lymphocytes of the patient and apparently
escaped complete NMD in this tissue. The status of the
mutant BMPR2 mRNA in the lung of the patient is
unknown. However, if the mutant BMPR2 mRNA also
escaped complete degradation by NMD in the lung tissue of
our patient, it is then presumed that the severely truncated
mutant protein was unable to interfere effectively with the
function of the wild-type BMPR2 protein in a dominant-
negative manner. Thus, one would predict that this patient
probably developed PAH through haploinsufﬁciency of the
BMPR2 protein [17].
Conclusion
Clinical testing for BMPR2 mutations is appropriate care for
the management of patients with a family history of PAH
regardless of the age at presentation as detection of family-
speciﬁc mutations can be used to counsel family members
at risk for developing PAH. Identiﬁcation and analysis of
different mutations will help understand the disease at a
genetic level and explore treatment options that can be
offered to patients and their families with HPAH.The future
holds promise for targeting therapies at a molecular level.
Prior to proceeding with presymptomatic genetic test-
ing, counseling to discuss the complexity of this disease
and the reduced risk for developing the disease in the
presence of the mutation is required.
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